Bleeding News and Research

RSS

Cheap drug that prevents bleeding may save 100,000 lives each year: Study

Researchers have shown that a cheap and easy to use drug that stops bleeding may save up to 100,000 lives each year from injuries associated with road accidents and violence. The study was published this Tuesday in the acclaimed international journal The Lancet and was conducted by doctors at the London School of Hygiene and Tropical Medicine.

14 Jun 2010

Blood flow interruption during renal surgery can increase risk of chronic kidney disease

Interrupting the blood flow for more than 20 to 25 minutes during kidney cancer (http://www.mayoclinic.org/kidney-cancer/research.html) surgery leads to a greater risk for patients developing chronic kidney disease, a Mayo Clinic and Cleveland Clinic collaborative research team has found. The study was published today in the journal, European Urology.

14 Jun 2010

Chiasma successfully completes Phase I clinical study of Octreolin

Chiasma, Inc., a privately held biopharma company, announced that it has successfully completed a Phase I clinical study evaluating the safety and pharmacokinetics (PK) of its proprietary product Octreolin, which contains the active ingredient octreotide actetate and is administered orally

14 Jun 2010

Dabigatran Etexilate anticoagulant as effective as Enoxaparin in preventing venous thromboembolism

Data from the RE-NOVATE® II study presented today at the 15th Annual Congress of the European Hematology Association (EHA) have shown that dabigatran etexilate 220mg once daily is as effective and safe as enoxaparin 40mg in preventing venous thromboembolism (VTE) after total hip replacement surgery.

11 Jun 2010

Repros receives FDA confirmation on lifting of full clinical hold on Proellex

Repros Therapeutics Inc. today announced it has received written confirmation from the FDA noting the full clinical hold on Proellex® has been lifted. The Company will be allowed to run a single study under the new partial clinical hold status. The new low dose study is designed to explore both safety and signals of efficacy in an escalating dose fashion.

11 Jun 2010

Effectiveness of combination band ligation and nadolol for first variceal bleeding not established

A controlled trial conducted by researchers at the E-DA Hospital in Kaohsiung, Taiwan, suggests that a combination of band ligation and nadolol may not be the most effective prophylaxis for first variceal bleeding resulting from cirrhosis. Results of this study appear in the July issue of Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases (AASLD).

10 Jun 2010

Cognitive-behavioral, skills-based treatment intervention program shows promise for teenagers with IBD

Disease is a private matter to many of us. For many reasons, we want to keep it to ourselves, and no cluster of disorders challenges patients' need for privacy more than inflammatory bowel disease.

10 Jun 2010

Researchers develop new tool for removing blood clots in brain

When someone suffers a stroke, time is critical--more than a million brain cells die each minute, starved of nourishment due to critical damage in a cerebral blood vessel.

10 Jun 2010

Researchers compare effectiveness of IB and AMP in high-risk patients

Major amputation is often selected over infrainguinal bypass in patients with severe systemic comorbidities because of a presumed decrease in risk of perioperative morbidity and mortality. To investigate this presumption, researchers from the Division of Vascular and Endovascular Surgery at the Brigham and Women's Hospital in Boston undertook a risk-adjusted comparison of early postoperative morbidity and mortality of high-risk patients undergoing infrainguinal bypass and major amputation.

9 Jun 2010

Promising technique to curb devastating effects of strokes

A clot vacuum cleaner that sucks out stroke-producing blockages from blood vessels in the brain sounds like science fiction. But 27 Calgary patients who were rescued from massive strokes know the endovascular procedure is for real, Dr. Mayank Goyal told the Canadian Stroke Congress today.

9 Jun 2010

Vital Therapies commences enrollment in ELAD SILVER trial for acute-on-chronic liver failure

Vital Therapies, Inc., (VTI) is pleased to announce that the first two subjects have been enrolled at King's College Hospital in London in the expansion of its SILVER (Stabilization In LiVER failure) clinical trial in Europe. The trial is evaluating whether VTI's biological cellular therapy product, ELAD®, can prevent deterioration of liver function and improve the survival of patients with acute-on-chronic liver failure (ACLF).

9 Jun 2010

Final results from Phase 1 trial of OGX-427 for treating solid tumors presented at ASCO 2010

OncoGenex Pharmaceuticals, Inc. today announced final results from a Phase 1 trial. The primary purpose of this trial was to evaluate the safety and tolerability of OGX-427 up to doses of 1000 mg for the treatment of various solid tumors. Patients enrolled had a diagnosis of castrate resistant prostate cancer, breast cancer, ovarian cancer or non-small cell lung cancer.

8 Jun 2010

EKOS receives $2.7M grant to develop product for treatment of ICH

EKOS Corporation announced today that they received a $2.7 million grant from the National Institutes of Health for the development of a product to provide therapy for intracerebral hemorrhagic stroke.

7 Jun 2010

CryoLife purchases patent involving formulation, use of recombinant human serum albumin and gluteraldehyde

CryoLife, Inc., an implantable biological medical device and cardiovascular tissue processing company whose products include BioGlue Surgical Adhesive, announced today that it has completed the purchase of U.S. patent # 6,329,337. The patent involves the formulation and use of recombinant human serum albumin and gluteraldehyde, and now becomes part of CryoLife's protein hydrogel patent portfolio, which includes BioGlue.

7 Jun 2010

Clivatuzumab tetraxetan shows promising results in patients with metastatic pancreatic cancer

Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that its proprietary antibody, clivatuzumab tetraxetan, labeled with yttrium-90 plus low-dose gemcitabine continues to produce promising efficacy results in patients with previously untreated, inoperable, locally advanced or metastatic pancreatic cancer.

7 Jun 2010

FDA approves 45mm GORE TAG Thoracic Endoprosthesis device

W. L. Gore & Associates (Gore) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) to market a 45 mm diameter version of the GORE® TAG® Thoracic Endoprosthesis for treatment of aneurysms of the descending thoracic aorta. The larger diameter device allows treatment of TAAs with proximal and distal neck diameters ranging from 37 - 42 mm and is now available for commercial use in the U.S.

7 Jun 2010

Vandetanib in combination with chemotherapy improves progression-free survival in patients with lung cancer

When combined with standard chemotherapy, an international Phase III trial has shown that the oral targeted therapy vandetanib improves progression-free survival for patients with advanced non-small cell lung cancer, according to research from The University of Texas MD Anderson Cancer Center.

5 Jun 2010

Phase 1B clinical study with PMX-60056 meets safety and efficacy endpoints: PolyMedix

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has successfully completed a second Phase 1B clinical safety and pilot efficacy study with PMX-60056, a small synthetic molecule designed to reverse heparin and low molecular weight heparin anticoagulants.

3 Jun 2010

Top physicians offer health advice to help people survive during summer

This summer a variety of top physicians at NewYork-Presbyterian Hospital are offering health advice to help survive the travails that come with one of the most active seasons of the year.

3 Jun 2010

Ablation technique as affective as conventional surgery for treating kidney cancer

A minimally invasive technique used to destroy kidney tumors with an electrically controlled heating probe showed similar effectiveness as surgical removal of tumors in curbing cancer recurrence rates for up to five years after treatment.

3 Jun 2010

Bleeding News and Research

Cheap drug that prevents bleeding may save 100,000 lives each year: Study

Blood flow interruption during renal surgery can increase risk of chronic kidney disease

Chiasma successfully completes Phase I clinical study of Octreolin

Dabigatran Etexilate anticoagulant as effective as Enoxaparin in preventing venous thromboembolism

Repros receives FDA confirmation on lifting of full clinical hold on Proellex

Effectiveness of combination band ligation and nadolol for first variceal bleeding not established

Cognitive-behavioral, skills-based treatment intervention program shows promise for teenagers with IBD

Researchers develop new tool for removing blood clots in brain

Researchers compare effectiveness of IB and AMP in high-risk patients

Promising technique to curb devastating effects of strokes

Vital Therapies commences enrollment in ELAD SILVER trial for acute-on-chronic liver failure

Final results from Phase 1 trial of OGX-427 for treating solid tumors presented at ASCO 2010

EKOS receives $2.7M grant to develop product for treatment of ICH

CryoLife purchases patent involving formulation, use of recombinant human serum albumin and gluteraldehyde

Clivatuzumab tetraxetan shows promising results in patients with metastatic pancreatic cancer

FDA approves 45mm GORE TAG Thoracic Endoprosthesis device

Vandetanib in combination with chemotherapy improves progression-free survival in patients with lung cancer

Phase 1B clinical study with PMX-60056 meets safety and efficacy endpoints: PolyMedix

Top physicians offer health advice to help people survive during summer

Ablation technique as affective as conventional surgery for treating kidney cancer

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News